Toilet seats with high tech sensors might be the non-invasive technology of the future that could help reduce hospital return rates of individuals with heart disease.
Heart failure is one of the leading causes of adults admitted to hospitals and more than six million adults in the United States have heart disease, according to the American Heart Association. Re-hospitalizations occur in some instances within 30 days to 6-months of initial treatment. Having a way to intercept these rehospitalizations might afford patients improved care and decrease costs.
A joint project by researchers at Rochester Institute of Technology and the University of Rochester Medical Center (URMC), will determine if in-home monitoring can successfully monitor vital signs and reduce risk and costly re-hospitalization rates for people with heart failure. The five-year, $2.9 million venture, is funded by the National Institutes of Health (NIH).
Photo by: A. Sue Weisler, RIT University Communications
New York, NY–October 1, 2020–A promising new COVID-19 rapid-testing technology platform developed by Rover Diagnostics and Columbia Engineering has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies. The affordable, portable, and ultrafast point-of-care Rover platform provides reverse transcription polymerase chain reaction (RT-PCR) results in eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.
Widely used since the 1980s for both clinical and research purposes, RT-PCR has been the gold standard for molecular diagnostic testing for decades. But because traditional PCR requires typically 45 minutes and trained